Nature Communications (Jun 2020)
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
- Stefanie de Groot,
- Rieneke T. Lugtenberg,
- Danielle Cohen,
- Marij J. P. Welters,
- Ilina Ehsan,
- Maaike P. G. Vreeswijk,
- Vincent T. H. B. M. Smit,
- Hiltje de Graaf,
- Joan B. Heijns,
- Johanneke E. A. Portielje,
- Agnes J. van de Wouw,
- Alex L. T. Imholz,
- Lonneke W. Kessels,
- Suzan Vrijaldenhoven,
- Arnold Baars,
- Elma Meershoek-Klein Kranenbarg,
- Marjolijn Duijm-de Carpentier,
- Hein Putter,
- Jacobus J. M. van der Hoeven,
- Johan W. R. Nortier,
- Valter D. Longo,
- Hanno Pijl,
- Judith R. Kroep,
- Dutch Breast Cancer Research Group (BOOG)
Affiliations
- Stefanie de Groot
- Department of Medical Oncology, Leiden University Medical Center
- Rieneke T. Lugtenberg
- Department of Medical Oncology, Leiden University Medical Center
- Danielle Cohen
- Department of Pathology, Leiden University Medical Center
- Marij J. P. Welters
- Department of Medical Oncology, Leiden University Medical Center
- Ilina Ehsan
- Department of Medical Oncology, Leiden University Medical Center
- Maaike P. G. Vreeswijk
- Department of Human Genetics, Leiden University Medical Center
- Vincent T. H. B. M. Smit
- Department of Pathology, Leiden University Medical Center
- Hiltje de Graaf
- Department of Medical Oncology, Medical center Leeuwarden
- Joan B. Heijns
- Department of Medical Oncology, Amphia
- Johanneke E. A. Portielje
- Department of Medical Oncology, Leiden University Medical Center
- Agnes J. van de Wouw
- Department of Medical Oncology, Viecuri
- Alex L. T. Imholz
- Department of Medical Oncology, Deventer hospital
- Lonneke W. Kessels
- Department of Medical Oncology, Deventer hospital
- Suzan Vrijaldenhoven
- Department of Medical Oncology, Noordwest hospital group, location Alkmaar
- Arnold Baars
- Department of Medical Oncology, Hospital Gelderse vallei
- Elma Meershoek-Klein Kranenbarg
- Department of Surgery, Leiden University Medical Center
- Marjolijn Duijm-de Carpentier
- Department of Surgery, Leiden University Medical Center
- Hein Putter
- Department of Medical Statistics and Bioinformatics, Leiden University Medical Center
- Jacobus J. M. van der Hoeven
- Department of Medical Oncology, Leiden University Medical Center
- Johan W. R. Nortier
- Department of Medical Oncology, Leiden University Medical Center
- Valter D. Longo
- Longevity Institute, School of Gerontology, and Department of Biological Sciences, University of Southern California
- Hanno Pijl
- Department of Endocrinology, Leiden University Medical Center
- Judith R. Kroep
- Department of Medical Oncology, Leiden University Medical Center
- Dutch Breast Cancer Research Group (BOOG)
- DOI
- https://doi.org/10.1038/s41467-020-16138-3
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 9
Abstract
Preclinical evidence suggests that a fasting mimicking diet (FMD) can make cancer cells more vulnerable to chemotherapy, while protecting normal cells. In this randomized phase II clinical trial of 131 patients with HER2 negative early stage breast cancer, the authors demonstrate that FMD is safe and enhances the effects of neoadjuvant chemotherapy on radiological and pathological tumor response.
